Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection

Journal of Infectious Diseases

Volumn 182, Issue 3, 2000, Pages 950-954

  Smith, Don ^a   Berrey, M Michelle ^b,c   Robertson, M ^d   Mehrotra, D ^d   Markowitz, Martin ^e   Perrin, Luc ^f   Clumeck, Nathan ^g   Lazzarin, Adriano ^h   Burckhardt, Beat ⁱ   Weber, R ^j   Corey, Lawrence ^b   Cooper, David A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GLAXOSMITHKLINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^f Hôpital Cantonal   (Switzerland)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; AUSTRALIA; BELGIUM; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LYMPHOCYTE COUNT; MALE; NAUSEA; NEPHROLITHIASIS; PRIORITY JOURNAL; SWITZERLAND; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; ZIDOVUDINE;

EID: 0033823552     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315753     Document Type: Article

References (15)

1. + T cell responses associated with control of viremia
2. Virological and serological markers of rapid progression to AIDS after HIV-1 seroconversion
3. + T cells during primary HIV-1 infection
4. Cytotoxic T cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
5. Predictors of rapid progression to AIDS in HIV-1 seroconverters
6. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. ACTG Group 320 Study Team
7. Longitudinal data analysis using generalised linear models
8. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
9. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
10. Report of the NIH panel to define principles of therapy of HIV infection
11. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
12. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
13. Decay characteristics of HIV-1 infected compartments during combination therapy
14. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion
15. Control of HIV despite discontinuation of antiretroviral therapy